Regeneron rises after quarterly profit beat
30/01/2026 14:38
** Shares of drugmaker Regeneron Pharmaceuticals REGN.O rise 2% to $764.63 ** Co reports Q4 adj. profit of $11.44 per share vs. analysts' estimates of $10.62 per share - LSEG data ** Posts quarterly revenue of $3.88 billion, vs. estimates of $3.8 billion ** REGN rose ~8% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)